JUVIA™ FOR HEALTHCARE PROFESSIONALS
The revolutionary gut supplement that will improve your patients’ lives.
We’re on a mission to help your patients with IBS free themselves from restrictive diets and endless ‘solutions’ that just don’t work.
GPS AND PEOPLE WITH IBS FEEL FRUSTRATED AT THE LACK OF EFFECTIVE TREATMENTS¹
JUVIA Digestive Balance Formula is backed by cutting-edge science pioneered by Professor John Hunter, formerly of Addenbrooke’s Hospital, and Dr Rosemary Waring, University of Birmingham, leading investigators in the areas of gut health and metabolic disorders.
JUVIA contains ERME™ (Enzyme-Rich Malt Extract), a unique natural ingredient derived from 100% sustainable barley. Our scientists discovered that the active digestive enzymes in ERME help break down carbohydrates before they can cause symptoms such as bloating, stomach cramps, constipation and diarrhoea, which are associated with IBS. This can mean no more restrictive diets or worrying where the bathroom is and freedom to live your life.
BACKED BY SCIENCE AND GUT EXPERTS
The research that has led to JUVIA was the first to establish the role that bacteria and fermentation plays in gut health. Published in the Lancet back in 1998 by Professor Hunter, the research⁴ led to an understanding that when the small intestine doesn’t digest food completely, especially carbohydrates, it can cause malfermentation in the large intestine. In turn, this can lead to the growth of unhealthy flora. This imbalance can irritate the gut.
Prof. Hunter has been published in:
ERME - THE ONLY INGREDIENT OF ITS KIND
To the best of our knowledge, ERME is the first product that attempts to specifically address the causes and the symptoms of certain types of IBS by optimising carbohydrate metabolism and mal-fermentation.
Our latest study was in patients with chronic constipation, which showed statistically significant decreases in constipation (KESS) score, abdominal pain and bloating. Read more in BMJ/Gut
HOW ERME WORKS
Our research suggests ERME works in two ways − it consists of a range of enzymes, including amylases and glucanases, which break down starch and plant materials into glucose and other simple carbohydrates early in the digestive process and provide energy. This means that much less starch is available for mal-fermentation in the lower gut.
The enzymes are surrounded by a matrix comprised mostly of malt polysaccharides, which protects the enzymes as they pass through the stomach. The matrix also re-balances the naturally-existing microbiome, improving the levels of ‘good’ bacteria. Unlike probiotics, alien bacterial species are not introduced.
An initial pilot study showed that IBS sufferers’ symptoms were significantly improved after taking the recommended dosage. Hydrogen breath levels (a marker for poor carbohydrate metabolism) after eating bread were significantly lower with ERME vs Control.
Professor Hunter's work also showed that when certain carbohydrates are restricted in the diet, IBS symptoms and malfermentation are reduced².
An open-label pilot study of 15 patients showed that after 4 weeks of ERME, the overall constipation score was significantly reduced as determined by a Knowles-Eckersley-Scott Symptoms questionnaire. Bloating, pain and flatulence were also significantly reduced.
ERME has been investigated in a randomised, placebo-controlled, double-blind study examining a number of IBS symptoms, lifestyle factors, biomarkers and using the cutting-edge technique metagenomics (identifying the species in the microbiome by looking at the DNA/RNA). This is important because conventional culture techniques cannot identify most gut bacteria. Results will be available later this year.
Latest study with the NHS: How JUVIA benefits patients with IBS, Wales
Our commitment to providing the most up-to-date scientific knowledge remains unwavering. As part of our continual research efforts, we are currently engaged in a study with the NHS on the benefits of JUVIA on patients with Irritable Bowel Syndrome (IBS). Our aim is to ensure that you receive the most cutting-edge information available.
HOW DOES JUVIA HELP THE HEALTHCARE INDUSTRY?
We can help reduce the number of patients with IBS going to their GPs. As it's the most common gastrointestinal condition seen by GPs³, it costs the NHS over £75 million³ a year.
- Törnblom H, Goosey R, Wiseman G, Baker S, Emmanuel A. Understanding symptom burden and attitudes to irritable bowel syndrome with diarrhoea: Results from patient and healthcare professional surveys. United European Gastroenterol J. 2018 Nov; 6(9): 1417–1427. PMCID: PMC6206540; PMID: 30386615
- King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. The Lancet. Volume 352, Issue 9135, 10 October 1998, Pages 1187-1189 https://pubmed.ncbi.nlm.nih.gov/9777836/
- Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut. 2000 Jan;46(1):78-82. doi: 10.1136/gut.46.1.78. PMID: 10601059; PMCID: PMC1727778.
- Alun Jones V, Shorthouse M, McLaughlan P, Workman E, Hunter JO. Food Intolerance: A major factor in the pathogenesis of Irritable Bowel Syndrome. Lancet ii: 1115-1117 198 https://pubmed.ncbi.nlm.nih.gov/6128447/